<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H2067749D2A9F4D45AC2FF8BF7636DE71" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 1266 IH: Combating Illicit Xylazine Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-02-12</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1266</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250212">February 12, 2025</action-date><action-desc><sponsor name-id="P000613">Mr. Panetta</sponsor> (for himself, <cosponsor name-id="P000048">Mr. Pfluger</cosponsor>, <cosponsor name-id="B001257">Mr. Bilirakis</cosponsor>, <cosponsor name-id="P000614">Mr. Pappas</cosponsor>, <cosponsor name-id="F000471">Mr. Fitzgerald</cosponsor>, <cosponsor name-id="R000305">Ms. Ross</cosponsor>, <cosponsor name-id="C001120">Mr. Crenshaw</cosponsor>, <cosponsor name-id="H001090">Mr. Harder of California</cosponsor>, <cosponsor name-id="D000617">Ms. DelBene</cosponsor>, <cosponsor name-id="M001215">Mrs. Miller-Meeks</cosponsor>, <cosponsor name-id="P000620">Ms. Pettersen</cosponsor>, <cosponsor name-id="C001067">Ms. Clarke of New York</cosponsor>, <cosponsor name-id="D000530">Mr. Deluzio</cosponsor>, <cosponsor name-id="M001223">Mr. Magaziner</cosponsor>, <cosponsor name-id="B001298">Mr. Bacon</cosponsor>, <cosponsor name-id="O000019">Mr. Obernolte</cosponsor>, <cosponsor name-id="C001059">Mr. Costa</cosponsor>, <cosponsor name-id="B001306">Mr. Balderson</cosponsor>, <cosponsor name-id="B001300">Ms. Barragán</cosponsor>, <cosponsor name-id="C001133">Mr. Ciscomani</cosponsor>, <cosponsor name-id="C001126">Mr. Carey</cosponsor>, <cosponsor name-id="B000740">Mrs. Bice</cosponsor>, <cosponsor name-id="C001119">Ms. Craig</cosponsor>, <cosponsor name-id="N000188">Mr. Norcross</cosponsor>, <cosponsor name-id="F000480">Mr. Fong</cosponsor>, <cosponsor name-id="T000478">Ms. Tenney</cosponsor>, <cosponsor name-id="F000466">Mr. Fitzpatrick</cosponsor>, <cosponsor name-id="B001309">Mr. Burchett</cosponsor>, <cosponsor name-id="D000631">Ms. Dean of Pennsylvania</cosponsor>, <cosponsor name-id="C001068">Mr. Cohen</cosponsor>, <cosponsor name-id="D000230">Mr. Davis of North Carolina</cosponsor>, <cosponsor name-id="C001110">Mr. Correa</cosponsor>, <cosponsor name-id="W000806">Mr. Webster of Florida</cosponsor>, <cosponsor name-id="C001129">Mr. Collins</cosponsor>, <cosponsor name-id="S001201">Mr. Suozzi</cosponsor>, and <cosponsor name-id="H001086">Mrs. Harshbarger</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HJU00">the Judiciary</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To prohibit certain uses of xylazine, and for other purposes.</official-title></form><legis-body id="H83FC12F17D07465FAB6BF513CF7E2D8A" style="OLC"><section id="HADFF36FDEE124157BD27E2EB57E54295" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This title may be cited as the <quote><short-title>Combating Illicit Xylazine Act</short-title></quote>.</text></section><section id="HC70CABEA225A414688CA57F3C6351E57"><enum>2.</enum><header>Definitions</header><subsection id="HAB19506F59BE492BBCAE3B85805F5D44"><enum>(a)</enum><header>In general</header><text>In this title, the term <term>xylazine</term> has the meaning given the term in paragraph (60) of section 102 of the Controlled Substances Act, as added by subsection (b) of this section.</text></subsection><subsection id="H625DA3CFC92C444B9BA9973B44678D87"><enum>(b)</enum><header>Controlled substances act</header><text>Section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HA643072F49904930906F33BB205AEDA5"><paragraph id="H5C8E16472D5B407F81EB978171ED20E3" indent="up1"><enum>(60)</enum><text>The term <term>xylazine</term> means the substance xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection></section><section id="HEF31DC2E06964F9C8A596D5B01317F6D"><enum>3.</enum><header>Adding xylazine to schedule III</header><text display-inline="no-display-inline">Schedule III of section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" display-inline="no-display-inline" id="HA3F397BC2F564FA387F84AE65F1D5A4C"><subsection commented="no" display-inline="no-display-inline" id="H48DF01B66D65416A8CFF26CB7C96B1B7"><enum>(f)</enum><text display-inline="yes-display-inline">Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of xylazine.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></section><section id="HA8E76EA63FF34363A4B76C6BC2512A55"><enum>4.</enum><header>Amendments</header><subsection commented="no" display-inline="no-display-inline" id="H12A6236AE5F74C3D99F82B1CD65A23F4"><enum>(a)</enum><header>Amendment</header><text display-inline="yes-display-inline">Section 102 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802</external-xref>) is amended by striking paragraph (27) and inserting the following: </text><quoted-block style="OLC" display-inline="no-display-inline" id="H2A3D1D769EE14CB99DE55F2FD40BFD6D"><paragraph commented="no" display-inline="no-display-inline" id="HAB2EE8FBD57945729143BC9FC8CFB8C9" indent="up1"><enum>(27)</enum><subparagraph commented="no" display-inline="yes-display-inline" id="H47A5A74734E34460AF0186FF74D8DBD0"><enum>(A)</enum><text display-inline="yes-display-inline">Except as provided in subparagraph (B), the term <term>ultimate user</term> means a person who has lawfully obtained, and who possesses, a controlled substance for the use by the person or for the use of a member of the household of the person or for an animal owned by the person or by a member of the household of the person.</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" indent="up1" id="H5B7229BB0C424F7D8F600A2C16520D32"><enum>(B)</enum><clause commented="no" display-inline="yes-display-inline" id="H78F9C14B80FA4F35972E82D85477E3E9"><enum>(i)</enum><text>In the case of xylazine, other than for a drug product approved under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/355">21 U.S.C. 355</external-xref>), the term <term>ultimate user</term> means a person—</text><subclause commented="no" display-inline="no-display-inline" indent="up1" id="H006B5809D81341D4AFE947FACC34A5D7"><enum>(I)</enum><text display-inline="yes-display-inline">to whom xylazine was dispensed by—</text><item commented="no" display-inline="no-display-inline" id="H7A09DF9518AE40A195A0E67151239B57"><enum>(aa)</enum><text display-inline="yes-display-inline">a veterinarian registered under this Act; or</text></item><item commented="no" display-inline="no-display-inline" id="H25052EB80FB64BB4BD13AAE79E32F000"><enum>(bb)</enum><text>a pharmacy registered under this Act pursuant to a prescription of a veterinarian registered under this Act; and</text></item></subclause><subclause commented="no" display-inline="no-display-inline" indent="up1" id="H5EA87EA5CFB74D7DB5970D67CDE92F17"><enum>(II)</enum><text>who possesses xylazine for—</text><item commented="no" display-inline="no-display-inline" id="H424C964212C24DF2A2F1205A40B5A69C"><enum>(aa)</enum><text>an animal owned by the person or by a member of the household of the person;</text></item><item commented="no" display-inline="no-display-inline" id="H37803575E9FC445AB6DC7A03C972E03F"><enum>(bb)</enum><text display-inline="yes-display-inline">an animal under the care of the person;</text></item><item commented="no" display-inline="no-display-inline" id="H7FC5DC0B92294967A0AAAC94BAF626C8"><enum>(cc)</enum><text display-inline="yes-display-inline">use in government animal-control programs authorized under applicable Federal, State, Tribal, or local law; or</text></item><item commented="no" display-inline="no-display-inline" id="HFD424F9CF46A4F388E252D1F8FE3FFA8"><enum>(dd)</enum><text display-inline="yes-display-inline">use in wildlife programs authorized under applicable Federal, State, Tribal, or local law. </text></item></subclause></clause><clause commented="no" display-inline="no-display-inline" indent="up1" id="H1B46519EA3B0422C8B9BDCF0E6A446D5"><enum>(ii)</enum><text display-inline="yes-display-inline">In this subparagraph, the term <term>person</term> includes—</text><subclause commented="no" display-inline="no-display-inline" id="HB7C788739FF64FF1B467CC837AAE302A"><enum>(I)</enum><text display-inline="yes-display-inline">a government agency or business where animals are located; and</text></subclause><subclause commented="no" display-inline="no-display-inline" id="HCD7A2BA630884BB4A9F382D06EB008C8"><enum>(II)</enum><text display-inline="yes-display-inline">an employee or agent of an agency or business acting within the scope of their employment or agency.</text></subclause></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HE33FCF45586E446DBC616CB6D94BA3C8"><enum>(b)</enum><header>Facilities</header><text>An entity that manufactures xylazine, as of the date of enactment of this Act, shall not be required to make capital expenditures necessary to install the security standard required of schedule III of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>) for the purposes of manufacturing xylazine.</text></subsection><subsection id="H0E6D6FEC16F44F20BC162BFBEA2DD7FA"><enum>(c)</enum><header>Labeling</header><text>The requirements related to labeling, packaging, and distribution logistics of a controlled substance in schedule III of section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>) shall not take effect for xylazine until the date that is 1 year after the date of enactment of this Act.</text></subsection><subsection id="HDE50BFAA7B474E259F30FF66B0B986B8"><enum>(d)</enum><header>Practitioner registration</header><text>The requirements related to practitioner registration, inventory, and recordkeeping of a controlled substance in schedule III of section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>) shall not take effect for xylazine until the date that is 60 days after the date of enactment of this Act. A practitioner that has applied for registration during the 60-day period beginning on the date of enactment of this Act may continue their lawful activities until such application is approved or denied.</text></subsection><subsection id="H32942BB16CB249418164B3EA0DEE2B3B"><enum>(e)</enum><header>Manufacturer transition</header><text>The Food and Drug Administration and the Drug Enforcement Administration shall facilitate and expedite the relevant manufacturer submissions or applications required by the placement of xylazine on schedule III of section 202(c) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/812">21 U.S.C. 812(c)</external-xref>).</text></subsection><subsection id="H5952223C8B8E4A1393C096E0F99B8AFE"><enum>(f)</enum><header>Clarification</header><text>Nothing in this title, or the amendments made by this title, shall be construed to require the registration of an ultimate user of xylazine under the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/801">21 U.S.C. 801 et seq.</external-xref>) in order to possess xylazine in accordance with subparagraph (B) of section 102(27) of that Act (<external-xref legal-doc="usc" parsable-cite="usc/21/802">21 U.S.C. 802(27)</external-xref>), as added by subsection (a) of this section. </text></subsection></section><section id="HEFD84FEF356F49F18ED3037D1820A85B"><enum>5.</enum><header>Arcos tracking</header><text display-inline="no-display-inline">Section 307(i) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/827">21 U.S.C. 827(i)</external-xref>) is amended—</text><paragraph id="H6F06CD9EECD24EAF8A07F5E426E03882"><enum>(1)</enum><text>in the matter preceding paragraph (1)—</text><subparagraph commented="no" display-inline="no-display-inline" id="H814FC78FCB2B49F9B4A5938A3E2C0C06"><enum>(A)</enum><text display-inline="yes-display-inline">by inserting <quote>or xylazine</quote> after <quote>gamma hydroxybutyric acid</quote>;</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H95B4C0E8E45E4B02A641D2551825C7C5"><enum>(B)</enum><text display-inline="yes-display-inline">by inserting <quote>or 512</quote> after <quote>section 505</quote>; and</text></subparagraph><subparagraph commented="no" display-inline="no-display-inline" id="H7DCA57CA722B4BA380BCBED2B63DBDB2"><enum>(C)</enum><text display-inline="yes-display-inline">by inserting <quote>respectively,</quote> after <quote>the Federal Food, Drug, and Cosmetic Act,</quote>; and</text></subparagraph></paragraph><paragraph id="H608896F7E22C474BBB1623530D2E7655"><enum>(2)</enum><text>in paragraph (6), by inserting <quote>or xylazine</quote> after <quote>gamma hydroxybutyric acid</quote>.</text></paragraph></section><section id="H8B1AD7BC92DC4973822A2D806D85BB8E"><enum>6.</enum><header>Sentencing Commission</header><text display-inline="no-display-inline">Pursuant to its authority under section 994(p) of title 28, United States Code, the United States Sentencing Commission shall review and, if appropriate, amend its sentencing guidelines, policy statements, and official commentary applicable to persons convicted of an offense under section 401 of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/841">21 U.S.C. 841</external-xref>) or section 1010 of the Controlled Substances Import and Export Act (<external-xref legal-doc="usc" parsable-cite="usc/21/960">21 U.S.C. 960</external-xref>) to provide appropriate penalties for offenses involving xylazine that are consistent with the amendments made by this title. In carrying out this section, the Commission should consider the common forms of xylazine as well as its use alongside other scheduled substances.</text></section><section id="HFDABDA39E3574F2E86C1160391B093B5"><enum>7.</enum><header>Report to Congress on xylazine</header><subsection id="H1DC93EFFB8824AAA8534D697890D1858"><enum>(a)</enum><header>Initial report</header><text>Not later than 18 months after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report on the prevalence of illicit use of xylazine in the United States and the impacts of such use, including—</text><paragraph id="H3AE9B71C748446188EA77FE1B3E3B231"><enum>(1)</enum><text>where the drug is being diverted;</text></paragraph><paragraph id="H6C368F1ABD4B46D6854EBB9A93FEE45D"><enum>(2)</enum><text>where the drug is originating; and</text></paragraph><paragraph id="HDDC95D0D223C4B60BC9D2FAC0E55EF76"><enum>(3)</enum><text>whether any analogues to xylazine, or related or derivative substances, exist and present a substantial risk of abuse.</text></paragraph></subsection><subsection id="HFB8A39129E3E4A6A9F8EB0627B451016"><enum>(b)</enum><header>Additional report</header><text>Not later than 4 years after the date of the enactment of this Act, the Attorney General, acting through the Administrator of the Drug Enforcement Administration and in coordination with the Commissioner of Food and Drugs, shall submit to Congress a report updating Congress on the prevalence and proliferation of xylazine trafficking and misuse in the United States.</text></subsection></section></legis-body></bill> 

